2004_Archive

[2009 Archive] [2008 Archive] [2007 Archive] [2006 Archive] [2005 Archive] [2004 Archive] [2003 Archive] [2009_Archive]

	11/14/2004 --	Stephen Kasnet Elected Chairman of the Board of Columbia Laboratories Edward Blechschmidt Elected Vice Chairman
	11/04/2004 --	Columbia Laboratories Reports Third Quarter 2004 Financial Results
	10/27/2004 --	Columbia Laboratories Receives European Approvals for STRIANT for Testosterone Replacement in Hypogonadal Men
	10/21/2004 --	Columbia Laboratories to Hold Third Quarter 2004 Financial Results Conference Call onNovember 4, 2004
	10/13/2004 --	Columbia Laboratories to Webcast Presentation at C.E. Unterberg, Towbin Specialty Pharmaceuticals Conference
	08/24/2004 --	Edward Blechschmidt and Stephen Kasnet Elected to Columbia Laboratories Board of Directors
	08/16/2004 --	Kronos Longevity Research Institute (KLRI) Changes Protocol for HRT Study
	08/04/2004 --	Columbia Laboratories Reports Second Quarter 2004 Financial Results
	08/03/2004 --	Published Phase III Study Shows STRIANT is a Safe and Effective TreatmentOption for Hypogonadal Men
	07/28/2004 --	Columbia Laboratories Reports Positive Results of Pregnancy Rate Pilot Study with Prochieve® 8%
	07/20/2004 --	Columbia Laboratories to Hold Second Quarter 2004 Financial Results Conference Call on August 4, 2004
	06/30/2004 --	Columbia Laboratories Completes Sale of OTC Portfolio
	06/28/2004 --	Columbia Laboratories Announces Submissions for Mutual Recognition Procedure in European Union for STRIANT SR
	06/18/2004 --	Columbia Laboratories Appoints Amy Raskopf as Manager of Investor Relations
	05/20/2004--	Columbia Laboratories Raises $6.4 Million through Sale of Common Stock
	05/18/2004 --	Columbia Laboratories to Webcast Presentation at UBS 2004 Specialty Pharmaceuticals Conference
	05/10/2004 --	Columbia Laboratories Reports First Quarter 2004 Financial Results
	05/04/2004 --	Comparative Study Shows STRIANT Consistently Achieves Normal Testosterone Levels
	05/03/2004 --	Columbia Laboratories to Hold Conference Call on First Quarter 2004 Financial Results
	04/20/2004 --	Columbia Laboratories announces Inclusion of Prochieve® 4% (progesterone gel) in National HRT Study
	04/07/2004 --	Columbia Announces Publication of Comparison Study of STRIANT (Testosterone Buccal System) and Testosterone Gel
	03/09/2004 --	Columbia Laboratories Reports Fourth Quarter And Year-End 2003 Financial Results Company Suspends Guidance For 2004
	03/04/2004 --	Columbia Receives Approval for STRIANT SR in the United Kingdom
	03/01/2004 --	Columbia Laboratories to Hold Conference Call on Fourth Quarter and Year End 2003 Financial Results
	02/23/2004 --	Columbia Laboratories to Webcast Presentation at 4th Annual Smith Barney Specialty Pharmaceuticals Conference
	02/10/2004 --	Columbia Laboratories to Move to NASDAQ National Market System February 13 First Trading Day on Exchange Under New Symbol CBRX
	02/05/2004 --	Columbia Laboratories Reports Positive Results from Phase II Study of Lidocaine Vaginal Gel for Dysmenorrhea
	01/28/2004 --	Columbia Laboratories and Innovex Agree to Restructure Sales Force; Columbia Establishes New Targeted Sales Force of 80 Representative